We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 205.00 | 202.00 | 205.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.33 | 195.58M |
TIDMOXB
RNS Number : 6454N
Oxford Biomedica PLC
25 September 2019
Director Dealings / Market Share Purchase
Oxford, UK - 25 September 2019: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Lorenzo Tallarigo, Chairman of the Group, has purchased 482 ordinary shares of 50p each ("Ordinary Shares") in the Company on 25 September 2019 on the London Stock Exchange at a price of 554.3p per share as set out below under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.
Under the market share purchase agreement, one-third of Dr. Tallarigo's fees as Chairman, after tax, are to be used to purchase ordinary shares in Oxford Biomedica plc on a monthly basis at the prevailing market price.
Following this purchase Dr. Tallarigo holds 51,534 ordinary shares representing 0.07% of the Company.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
1. Details of the person discharging material responsibilities/person closely associated a. Name Lorenzo Tallarigo 2. Reason for the notification a. Position/status Chairman b. Initial notification Initial notification /amendment 3. Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor a. Name Oxford Biomedica plc b. Legal Entity Identifier 213800S1GVQNXQ15K851 4. Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a. Description of Oxford Biomedica plc Ordinary Shares the financial of 50p each instrument, type GB00BDFBVT43 of instrument identification code b. Nature of the Purchase of ordinary shares transaction c. Currency GBP - British Pound d. Price(s) and volume(s) Price(s) Volume(s) GBP5.54 482 e. Aggregated information 482 * Aggregated volume GBP5.543 GBP2,671.73 * Price * Aggregated total f. Date of the transaction 2019-09-25 g. Place of the transaction London Stock Exchange, Main Market (XLON)
The issued share capital of the Group is 76,767,971 ordinary 50p shares.
-Ends-
For further information, please contact: Oxford Biomedica plc: Tel: +44 (0)1865 783 000 Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 480 people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHUVORRKKAKUAR
(END) Dow Jones Newswires
September 25, 2019 06:41 ET (10:41 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions